FORTIS HEALTHCARE Ltd (FORTIS) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-0.33%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 25.2%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 11.2%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹744.98

200-Day DMA ● Overlay

₹690.94

14-Day RSI ● Overlay

50.8 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹58,120 Cr

Large cap

Stock P/E (TTM) Valuation

54.4x

Price / EPS

Book Value (₹) Assets

₹131.0

P/B: 5.9x

ROE (%) Quality

11.2%

Net Profit / Equity

ROCE (%) Efficiency

13.4%

EBIT / Capital

Dividend Yield Yield

0.13%

Face Value: ₹10

Debt / Equity Solvency

0.35x

Manageable

EPS (TTM) Per Share

₹14.20

Trailing 12M

OPM (%) Spread

22.0%

EBITDA Margin

Free Cash Flow Cash

₹673.00 Cr

CFO - Capex

About FORTIS HEALTHCARE Ltd

FORTIS HEALTHCARE Ltd (FORTIS) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 15.8% × Turnover: 0.85x × Leverage: 1.35x = ROE: 11.2%

✓ Company Strengths (Pros)

• Maintains healthy operating profit margins of ~22.0%.
• TickerPulse fundamental algorithm rates overall quality at 80/100.

⚠ Key Considerations & Risks (Cons)

• Stock is trading at a premium of 5.9x its book value.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹9,506 Cr

Latest PAT

₹1,070 Cr

EPS (TTM)

₹14.20

OPM %

22.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹1,657 Cr	₹1,770 Cr	₹1,680 Cr	₹1,786 Cr	₹1,859 Cr	₹1,988 Cr	₹1,928 Cr	₹2,007 Cr	₹2,167 Cr	₹2,331 Cr	₹2,265 Cr	₹2,365 Cr	₹2,545 Cr
Operating Profit (EBITDA)	₹272.00 Cr	₹330.00 Cr	₹284.00 Cr	₹381.00 Cr	₹343.00 Cr	₹435.00 Cr	₹375.00 Cr	₹435.00 Cr	₹491.00 Cr	₹556.00 Cr	₹506.00 Cr	₹532.00 Cr	₹537.00 Cr
OPM %	16.0%	19.0%	17.0%	21.0%	18.0%	22.0%	19.0%	22.0%	23.0%	24.0%	22.0%	23.0%	21.0%
Interest Expense	₹31.00 Cr	₹32.00 Cr	₹33.00 Cr	₹35.00 Cr	₹35.00 Cr	₹36.00 Cr	₹45.00 Cr	₹68.00 Cr	₹70.00 Cr	₹75.00 Cr	₹86.00 Cr	₹84.00 Cr	₹80.00 Cr
Depreciation	₹79.00 Cr	₹84.00 Cr	₹87.00 Cr	₹92.00 Cr	₹91.00 Cr	₹95.00 Cr	₹97.00 Cr	₹102.00 Cr	₹101.00 Cr	₹106.00 Cr	₹120.00 Cr	₹122.00 Cr	₹122.00 Cr
Profit before Tax (PBT)	₹171.00 Cr	₹233.00 Cr	₹183.00 Cr	₹271.00 Cr	₹230.00 Cr	₹261.00 Cr	₹279.00 Cr	₹237.00 Cr	₹351.00 Cr	₹425.00 Cr	₹266.00 Cr	₹324.00 Cr	₹363.00 Cr
Net Profit (PAT)	₹124.00 Cr	₹184.00 Cr	₹134.00 Cr	₹203.00 Cr	₹174.00 Cr	₹193.00 Cr	₹254.00 Cr	₹188.00 Cr	₹267.00 Cr	₹329.00 Cr	₹197.00 Cr	₹271.00 Cr	₹273.00 Cr
EPS in ₹	₹1.48	₹2.30	₹1.78	₹2.37	₹2.20	₹2.34	₹3.28	₹2.44	₹3.45	₹4.26	₹2.57	₹3.52	₹3.53

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	₹3,966 Cr	₹4,199 Cr	₹4,574 Cr	₹4,561 Cr	₹4,469 Cr	₹4,632 Cr	₹4,030 Cr	₹5,718 Cr	₹6,298 Cr	₹6,893 Cr	₹7,783 Cr	₹9,128 Cr	₹9,506 Cr
Expenses	₹3,857 Cr	₹4,106 Cr	₹4,220 Cr	₹4,287 Cr	₹4,238 Cr	₹4,022 Cr	₹3,626 Cr	₹4,649 Cr	₹5,196 Cr	₹5,625 Cr	₹6,195 Cr	₹7,043 Cr	₹7,375 Cr
Operating Profit	₹109.00 Cr	₹92.00 Cr	₹354.00 Cr	₹274.00 Cr	₹231.00 Cr	₹610.00 Cr	₹404.00 Cr	₹1,069 Cr	₹1,101 Cr	₹1,268 Cr	₹1,588 Cr	₹2,085 Cr	₹2,131 Cr
OPM %	2.8%	2.2%	8%	6%	5%	13%	10%	19%	17%	18%	20%	23%	22%
Interest	₹152.00 Cr	₹133.00 Cr	₹229.00 Cr	₹258.00 Cr	₹337.00 Cr	₹205.00 Cr	₹166.00 Cr	₹147.00 Cr	₹129.00 Cr	₹131.00 Cr	₹184.00 Cr	₹314.00 Cr	₹325.00 Cr
Depreciation	₹235.00 Cr	₹225.00 Cr	₹222.00 Cr	₹239.00 Cr	₹233.00 Cr	₹292.00 Cr	₹291.00 Cr	₹301.00 Cr	₹316.00 Cr	₹342.00 Cr	₹386.00 Cr	₹449.00 Cr	₹470.00 Cr
Profit before Tax	-₹185.00 Cr	₹34.00 Cr	₹552.00 Cr	-₹912.00 Cr	-₹110.00 Cr	₹239.00 Cr	₹43.00 Cr	₹988.00 Cr	₹814.00 Cr	₹858.00 Cr	₹1,007 Cr	₹1,366 Cr	₹1,378 Cr
Net Profit	-₹130.00 Cr	₹42.00 Cr	₹479.00 Cr	-₹934.00 Cr	-₹224.00 Cr	₹91.00 Cr	-₹56.00 Cr	₹790.00 Cr	₹633.00 Cr	₹645.00 Cr	₹809.00 Cr	₹1,064 Cr	₹1,070 Cr
EPS in Rs	-3.10	0.40	8.14	-19.46	-3.96	0.77	-1.45	7.35	7.80	7.93	10.26	13.80	13.88

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	₹463.00 Cr	₹463.00 Cr	₹518.00 Cr	₹519.00 Cr	₹755.00 Cr	₹755.00 Cr	₹755.00 Cr	₹755.00 Cr	₹755.00 Cr	₹755.00 Cr	₹755.00 Cr	₹755.00 Cr
Reserves & Surplus	₹3,585 Cr	₹3,998 Cr	₹4,626 Cr	₹3,543 Cr	₹5,846 Cr	₹5,906 Cr	₹5,365 Cr	₹5,423 Cr	₹6,487 Cr	₹6,908 Cr	₹8,162 Cr	₹9,141 Cr
Borrowings (Debt)	₹1,784 Cr	₹1,513 Cr	₹2,217 Cr	₹1,962 Cr	₹2,010 Cr	₹1,594 Cr	₹1,531 Cr	₹1,255 Cr	₹926.00 Cr	₹1,155 Cr	₹2,475 Cr	₹3,473 Cr
Total Liabilities	₹7,592 Cr	₹7,232 Cr	₹9,588 Cr	₹8,479 Cr	₹11,486 Cr	₹11,036 Cr	₹10,866 Cr	₹11,516 Cr	₹12,089 Cr	₹12,971 Cr	₹13,377 Cr	₹15,833 Cr
Fixed Assets	₹4,218 Cr	₹3,642 Cr	₹5,419 Cr	₹4,992 Cr	₹8,477 Cr	₹8,802 Cr	₹8,799 Cr	₹9,416 Cr	₹9,426 Cr	₹9,874 Cr	₹10,424 Cr	₹12,230 Cr
Total Assets	₹7,592 Cr	₹7,232 Cr	₹9,588 Cr	₹8,479 Cr	₹11,486 Cr	₹11,036 Cr	₹10,866 Cr	₹11,516 Cr	₹12,089 Cr	₹12,971 Cr	₹13,377 Cr	₹15,833 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operations (CFO)	₹24.00 Cr	₹195.00 Cr	₹966.00 Cr	₹493.00 Cr	-₹179.00 Cr	₹172.00 Cr	₹485.00 Cr	₹865.00 Cr	₹822.00 Cr	₹1,100 Cr	₹1,424 Cr	₹1,601 Cr
Cash from Investing (CFI)	₹213.00 Cr	₹122.00 Cr	-₹1,001 Cr	-₹333.00 Cr	-₹3,279 Cr	₹63.00 Cr	-₹131.00 Cr	-₹501.00 Cr	-₹372.00 Cr	-₹889.00 Cr	-₹780.00 Cr	-₹1,537 Cr
Cash from Financing (CFF)	-₹304.00 Cr	-₹354.00 Cr	₹259.00 Cr	-₹672.00 Cr	₹4,257 Cr	-₹862.00 Cr	-₹143.00 Cr	-₹517.00 Cr	-₹471.00 Cr	-₹86.00 Cr	-₹714.00 Cr	₹164.00 Cr
Free Cash Flow (FCF)	-₹181.00 Cr	-₹162.00 Cr	₹689.00 Cr	₹437.00 Cr	-₹261.00 Cr	₹35.00 Cr	₹274.00 Cr	₹750.00 Cr	₹367.00 Cr	₹172.00 Cr	₹591.00 Cr	₹673.00 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days (DSO)	38	39	38	38	44	36	41	33	34	33	37	42
Inventory Days	25	23	23	24	22	30	29	33	31	24	23	24
Cash Conversion Cycle (Days)	-144	-156	-155	-217	-230	-161	-135	-112	-115	-107	-101	-99
ROCE %	0%	3%	11%	3%	6%	4%	2%	10%	10%	10%	12%	13%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹216.87 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹772.00

DCF Fair Value

₹216.87

Graham Number

₹204.58

Margin of Safety

-72.6%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹216.87

Premium / Overvalued (Margin: -72.6%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹211	₹209	₹207	₹205
10%	₹215	₹213	₹211	₹209
12%	₹219	₹217	₹215	₹213
14%	₹223	₹221	₹219	₹217

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹217	Fairly Valued
Benjamin Graham Number	₹205	Market Priced
Historical Sector P/E	₹312	Premium
EV / EBITDA Multiplier	₹811	In-Line
Free Cash Flow Yield Model	₹757	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 8/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

8 / 9 Pass

Altman Z-Score

4.35 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.35x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 22.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

31.17%

FIIs (Foreign)

25.20%

DIIs (Domestic)

32.23%

Government

0.15%

Public / Retail

11.40%

Swipe → to view historical quarters

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
+ Promoters	31.17%	31.17%	31.17%	31.17%	31.17%	31.17%	31.17%	31.17%	31.17%	31.17%	31.17%	31.17%
+ FIIs (Foreign Portfolio)	26.31%	23.72%	23.24%	23.31%	25.26%	26.77%	27.40%	27.18%	27.90%	27.84%	25.98%	25.20%
+ DIIs (Mutual Funds / Insurance)	26.55%	29.42%	31.14%	32.31%	30.73%	30.05%	29.46%	29.79%	29.14%	29.33%	31.35%	32.23%
+ Public (Retail & HNIs)	15.97%	15.71%	14.44%	13.22%	12.83%	12.02%	11.98%	11.87%	11.79%	11.65%	11.50%	11.40%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

FORTIS Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

FORTIS Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

FORTIS Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹988.16

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹864.64

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 54x P/E.

🐻 Bear Case (15%) -12.0%

₹679.36

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 20:17 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ FORTIS HEALTHCARE Ltd (FORTIS)	Target Stock	₹772.00	-0.33%	54.4x	11.2%	13.4%	0.35	₹58,120 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	20:17:19 IST	✓ Live Sync
Financial Statements (10Y)	FORTIS HEALTHCARE Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

FORTIS HEALTHCARE Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About FORTIS HEALTHCARE Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title